Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Dru... (rug DiscoveryInitiative includes represe...)

Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline

Date:10/7/2008

rug Discovery Initiative includes representatives of government agencies, philanthropic organizations, pharmaceutical companies, universities and other research institutions. Its most important goal is filling the pipeline for future TB drugs.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

For this Initiative, Lilly has opened access to its greatest assets, a library of 500,000 compounds. The company also is lending its immense drug discovery expertise and organizational savvy, and is contributing the latest, most innovative technologies used in drug discovery to be applied to the search for new drugs to fight TB. The $15 million Lilly has given to support this historic undertaking is part of Lilly's $135 million commitment to control MDR-TB through The Lilly MDR-TB Partnership, which mobilizes 18 partners on five continents to stop the spread of the disease and save lives. Additional information can be found at http://www.lillymdr-tb.com.

About IDRI

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most. For more information, go to http://www.idri.o
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
2. RG Global Corporate Update: First Coal Bed Methane Water Treatment Plant Near Completion; Expanding Water Treatment Applications
3. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
4. Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA
5. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
6. Lilly Declares Fourth-Quarter Dividend
7. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
10. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
11. Lilly Announces Termination of AIR Insulin Program

Post Your Comments:

Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Dru...(rug DiscoveryInitiative includes represe...)